Although blockade of acute cardiac effects of FGF23 might be not desirable, anti-FGFR4 therapy may protect from chronic cardiac effects of FGF23 and associated progression to irreversible cardiac injury as observed in patients with CKD. This evidence concerns the gene FGF23 and chronic kidney disease.